Envveno Medical Corp (NVNO) Stock Price, Quote & News

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 261 2900

Website: www.envveno.com

Address:

70 Doppler, Irvine, United States

Rco002 Apr. 22 at 10:56 PM

$NVNO lost my kids college fund with this. Now I’m turning tricks and jacking off punks underneath the Brooklyn bridge for $5 a pop. Thanks Berman.

0 · Reply

Biotech_Pharma_Investor Apr. 22 at 4:07 PM

$NVNO A spike here is long overdue

0 · Reply

cohunter9 Apr. 19 at 4:12 AM

$NVNO I limited losses with options. They have nothing, do not lose money here

0 · Reply

OfficialStocktwitsUser Apr. 18 at 2:07 AM

$NVNO RSI: 71.94, MACD: 0.1279 Vol: 0.46, MA20: 10.82, MA50: 10.71 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AtlasAnalysis Apr. 16 at 2:46 PM

$NVNO 100% feasible just need high volume

0 · Reply

BigGreenCandle Apr. 14 at 11:13 PM

$NVNO This POS never had any kind of move and now that it has a vapor thin float I'd love to see some stupid pump to $40. C'mon, Berman. Do something interesting for once.

0 · Reply

tuckerabbott Apr. 14 at 2:43 PM

$NVNO Complete Garbage.

0 · Reply

FDAvalid Apr. 12 at 7:15 PM

$GTI $NVNO $REPL THEY HAD A FDA LETTER IN 2021 SAYING THE TRIAL WOULD FAIL. THEY KEPT IT SECRET TO TAKE YOUR MONEY. THE ULTIMATE RUG PULL! 📜🕳️

0 · Reply

FDAvalid Apr. 11 at 12:42 AM

$GTI $NVNO $REPL good call hope people are wiser, there are better assets elsewhere, this company is done, lawsuits coming on Monday for failure to disclose material deficiency since 2021

0 · Reply

Sudhakar1990 Apr. 11 at 12:30 AM

$REPL At Monday’s market open, we might see a brief spike. But if bullish bag holders 🐂 take that as a signal to invest more, they could end up pouring money into a dead asset and lose it within hours. Ex: $NVNO $GTI

0 · Reply

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Mar 3, 2026, 2:40 PM EST - 7 weeks ago

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

Feb 4, 2026, 8:30 AM EST - 2 months ago

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 15, 2026, 8:00 AM EST - 3 months ago

enVVeno Medical Announces Reverse Stock Split

Nov 26, 2025, 8:48 AM EST - 5 months ago

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Nov 13, 2025, 5:00 PM EST - 5 months ago

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Oct 31, 2025, 8:05 AM EDT - 6 months ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 26, 2025, 8:45 AM EDT - 7 months ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 15, 2025, 8:45 AM EDT - 7 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 8 months ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 15, 2025, 9:21 AM EDT - 9 months ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 8:30 AM EDT - 9 months ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 4, 2025, 9:05 AM EDT - 9 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 1, 2025, 8:00 AM EDT - 9 months ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025, 8:45 AM EDT - 9 months ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jun 6, 2025, 8:05 AM EDT - 11 months ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025, 8:45 AM EDT - 1 year ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025, 8:00 AM EDT - 1 year ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025, 8:30 AM EDT - 1 year ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025, 9:00 AM EDT - 1 year ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Feb 28, 2025, 8:00 AM EST - 1 year ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025, 9:00 AM EST - 1 year ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:45 AM EST - 1 year ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025, 9:00 AM EST - 1 year ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024, 8:50 AM EST - 1 year ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 15, 2021, 8:05 AM EDT - 5 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 7, 2021, 8:05 AM EDT - 5 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Aug 19, 2021, 11:49 AM EDT - 5 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 8:00 AM EDT - 5 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 3, 2021, 8:58 AM EDT - 5 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:05 AM EDT - 5 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Jul 8, 2021, 9:05 AM EDT - 5 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Apr 23, 2021, 12:40 PM EDT - 5 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 5, 2021, 7:30 AM EDT - 5 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Jan 12, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions

Dec 21, 2020, 8:30 AM EST - 5 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Rco002 Apr. 22 at 10:56 PM

$NVNO lost my kids college fund with this. Now I’m turning tricks and jacking off punks underneath the Brooklyn bridge for $5 a pop. Thanks Berman.

0 · Reply

Biotech_Pharma_Investor Apr. 22 at 4:07 PM

$NVNO A spike here is long overdue

0 · Reply

cohunter9 Apr. 19 at 4:12 AM

$NVNO I limited losses with options. They have nothing, do not lose money here

0 · Reply

OfficialStocktwitsUser Apr. 18 at 2:07 AM

0 · Reply

AtlasAnalysis Apr. 16 at 2:46 PM

$NVNO 100% feasible just need high volume

0 · Reply

BigGreenCandle Apr. 14 at 11:13 PM

$NVNO This POS never had any kind of move and now that it has a vapor thin float I'd love to see some stupid pump to $40. C'mon, Berman. Do something interesting for once.

0 · Reply

tuckerabbott Apr. 14 at 2:43 PM

$NVNO Complete Garbage.

0 · Reply

FDAvalid Apr. 12 at 7:15 PM

$GTI $NVNO $REPL THEY HAD A FDA LETTER IN 2021 SAYING THE TRIAL WOULD FAIL. THEY KEPT IT SECRET TO TAKE YOUR MONEY. THE ULTIMATE RUG PULL! 📜🕳️

0 · Reply

FDAvalid Apr. 11 at 12:42 AM

$GTI $NVNO $REPL good call hope people are wiser, there are better assets elsewhere, this company is done, lawsuits coming on Monday for failure to disclose material deficiency since 2021

0 · Reply

Sudhakar1990 Apr. 11 at 12:30 AM

0 · Reply

LifeisaMeme Mar. 26 at 2:23 AM

$NVNO Its over for you Berman ICEMANJA gonna slap you in the face. LMAOOOOOOOOOOOOOOOOo

1 · Reply

Icemanja Mar. 24 at 3:19 PM

$NVNO Did the ready-to-go packaged SaVVE trial get lost in the mail? Or was Berman blowing smoke again? Curious to see the sell the news event that always happens here.

0 · Reply

Icemanja Mar. 16 at 1:20 PM

$NVNO The fraud Robert Berman and team still talking about Inari and Silk Road success , while procrastinating NVNO success. Hancock Jaffe - Failed , Heart Valve Failed , NVNO Merger Failed, Venovalve failed . Wall Street will never trust these clowns agian No matter what News they drop during trial. Maybe if they ever sell a product and turn a profit things might change.

0 · Reply

Cccris Mar. 12 at 6:08 PM

$NVNO High volume! Something is going on?

0 · Reply

Surfside89 Mar. 10 at 7:22 PM

$NVNO Don’t get fooled by the clown show running this company. I took a big loss here with the reverse split. Luckily I made it all back with $IBRX. Definitely recommend checking it out. Some big events happening soon. Do some DD and look at what’s going on with the company. GL

0 · Reply

STKH Mar. 9 at 6:20 PM

$GSIW 25$ now $NVNO 11.9 flo 600k

0 · Reply

Hvyripper Mar. 7 at 10:19 PM

$NVNO Funny how this thing became a POS pump board for penny stocks. Not so funny that i lost 6 figures in it.

1 · Reply

LifeisaMeme Mar. 7 at 3:01 AM

$NVNO Everyone load your puts. The ceo is a low IQ loser.

0 · Reply

Jimmag Mar. 5 at 8:49 PM

$NVNO why is this trash getting pumped? Keep going so i can unload what small amount of reverse split I have left.

0 · Reply

Flying_Trader2 Mar. 5 at 6:17 PM

$NVNO Ok, I'll bite, what's up with this POS company ?

0 · Reply

BillionerOfKing Mar. 4 at 10:08 PM

$NVNO Current Stock Price: $10.70 Contracts to trade: $7.5 NVNO May 15 2026 Call Entry: $0.10 Exit: $0.15 ROI: 57% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Miau051 Feb. 26 at 4:08 PM

$NVNO i like the Silence here

1 · Reply

Market Cap	8.52M
Revenue (ttm)	0.00
Net Income (ttm)	-19.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,700
Avg Vol	13,814
Day's Range	N/A - N/A
Shares Out	656,000.00
Stochastic %K	84%
Beta	1.09
Analysts	Hold
Price Target	$12.50